PVR and cancer: Additional studies employing anti-CD96 antibodies provided further support for targeting this pathway as a strategy to treat cancer (14, 15); however, the findings were confounded by the observation that anti-CD96 antibodies need not block the CD155-CD96 interaction to exert their antimetastatic effect (16).